Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383133 · ClinicalTrials.gov registry record · Early Phase 1
Studies of Sulfur Metabolism in Humans
A Early Phase 1 study of Metabolic Side Effects of Drugs, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT03383133 is a Early Phase 1 study of Metabolic Side Effects of Drugs that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03383133, a Early Phase 1 study of Metabolic Side Effects of Drugs, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The study test whether the NSAID allosteric site of human sulfotransferase 1A1 (SULT1A1) is operative in humans. The study will test the effects of mefenamic acid (MEF) on the sulfonation of acetaminophen (APAP, a SULT1A1 specific substrate) and dehydroepiandrosterone (DHEA, a SULT2A1 substrate). If the allosteric site is active in vivo, MEF is predicted to result in a decrease in sulfonation of APAP (MEF inhibits SULT with high affinity (Ki = 23 nM), and to have no effect on sulfonation of the DHEA (MEF has little or no effect on SULT2A1 activity).
Conditions Studied
Interventions
- DRUG SULT Allosteric Inhibition
Study Locations (1)
New York
- Albert Einstein Collage of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2023-02-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03383133
The ClinicalTrials.gov registry entry for NCT03383133 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Side Effects of Drugs appearing as the primary indexed condition, and to 1 intervention - of which SULT Allosteric Inhibition is the first listed.
NCT03383133 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03383133 about?
NCT03383133 is a clinical study titled "Studies of Sulfur Metabolism in Humans". The study test whether the NSAID allosteric site of human sulfotransferase 1A1 (SULT1A1) is operative in humans. The study will test the effects of mefenamic acid (MEF) on the sulfonation of acetaminophen (APAP, a SULT1A1 specific substrate) and dehydroepiandrosterone (DHEA, a SULT2A1 substrate). If...
What is the current status of trial NCT03383133?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-01-11. Estimated completion is 2023-02-02.
What conditions does trial NCT03383133 study?
This clinical trial studies the following conditions: Metabolic Side Effects of Drugs.
What interventions are being tested in trial NCT03383133?
The interventions under investigation include: SULT Allosteric Inhibition (DRUG).
Who is sponsoring clinical trial NCT03383133?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03383133 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.